Tag: Pure Tech Health

December 7, 2021 Off

Pure Tech kicks off study for its neuro conditions treatment candidate

By Dino Mustafić

PureTech Health has kicked off a clinical study of LYT-300 (oral allopregnanolone), its wholly-owned therapeutic candidate for the potential treatment of neurological and neuropsychological conditions, including depression, anxiety, sleep disorders, fragile X tremor-associated syndrome, essential tremor and epileptic disorders, among others. LYT-300 is the third clinical-stage, wholly-owned candidate from PureTech’s pipeline.